Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Efficacy, Acceptability, and Tolerability of Trazodone in Insomnia Symptoms: A Systematic Review and Dose-Response Meta-Analysis

AI Summary
  • Trazodone moderately improves subjective sleep quality versus placebo (Cohen's d 0.67), with substantial heterogeneity across trials.
  • Efficacy rises at low doses and plateaus near 50 mg/day; estimated ED50 15.2 mg/day and ED95 38.2 mg/day, exploratory.
  • Higher doses offer limited additional benefit and may reduce tolerability; possible dose-related rise in adverse event discontinuations and limited long-term data.
Summarise with AI (MRCPsych/FRANZCP)

Clin Drug Investig. 2026 Nov 12. doi: 10.1007/s40261-026-01607-2. Online ahead of print.

ABSTRACT

BACKGROUND AND OBJECTIVE: Trazodone is widely prescribed off label for insomnia symptoms, but the dose range that best balances efficacy with acceptability and tolerability remains uncertain. This systematic review and dose-response meta-analysis evaluated trazodone for insomnia symptoms, with emphasis on clinically relevant dose selection.

METHODS: We searched Embase, PubMed, Web of Science, and the Cochrane Library from inception to 17 November 2025, for randomized controlled trials comparing trazodone with placebo or different trazodone doses in patients with insomnia symptoms. Dose-response relationships were evaluated using a one-stage random-effects model with restricted cubic splines. The primary outcome was subjective sleep quality; secondary outcomes were all-cause dropout rate and dropout due to adverse events.

RESULTS: Thirteen randomized controlled trials involving 1366 participants were included. Compared with placebo, trazodone moderately improved subjective sleep quality (Cohen’s d = 0.67, 95% confidence interval [CI] 0.36-0.98; I2 = 80.86%; p < 0.01). The dose-response curve suggested that efficacy increased at lower doses and approached a plateau around 50 mg/day, although estimates in the higher-dose range were sparse and imprecise. The estimated 50% effective dose was 15.2 mg/day, and the 95% effective dose was 38.2 mg/day, but these estimates should be interpreted as exploratory rather than as precise dose targets. Conventional meta-analysis showed no clear difference in all-cause discontinuation or discontinuation due to adverse events, whereas dose-response analysis suggested a possible dose-related increase in adverse event-related discontinuation.

CONCLUSIONS: Trazodone was associated with short-term improvement in subjective sleep quality among heterogeneous populations with insomnia symptoms. The most observable benefit appears to occur at relatively low doses, while dose escalation may offer limited additional benefit and reduce tolerability. However, interpretation of the findings is limited by considerable clinical heterogeneity, sparse evidence at higher doses, and insufficient data on long-term efficacy and safety.

PROSPERO REGISTRATION: CRD420251232065.

PMID:43018915 | DOI:10.1007/s40261-026-01607-2

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD